Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jason A Roberts

Showing results (541-550 of 609) with videos related to

Pageof 61
Sort By:
Intensive Care Medicine|November 30, 2019
Antimicrobial de-escalation in critically ill patients: a position statement from a task force of the European Society of Intensive Care Medicine (ESICM) and European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Critically Ill Patients Study Group (ESGCIP)Alexis Tabah, Matteo Bassetti, Marin H Kollef, et al.
Trials|January 28, 2015
Meropenem versus piperacillin-tazobactam for definitive treatment of bloodstream infections due to ceftriaxone non-susceptible Escherichia coli and Klebsiella spp (the MERINO trial): study protocol for a randomised controlled trialPatrick N A Harris, Anton Y Peleg, Jon Iredell, et al.
Anesthesiology|March 2, 2017
Nebulization of Antiinfective Agents in Invasively Mechanically Ventilated Adults: A Systematic Review and Meta-analysisCandela Solé-Lleonart, Jean-Jacques Rouby, Stijn Blot, et al.
Clinical Pharmacokinetics|February 1, 2015
Reporting Guidelines for Clinical Pharmacokinetic Studies: The ClinPK StatementSalmaan Kanji, Meghan Hayes, Adam Ling, et al.
Microbiology Spectrum|January 9, 2024
Rapid nanopore sequencing and predictive susceptibility testing of positive blood cultures from intensive care patients with sepsisPatrick N A Harris, Michelle J Bauer, Lukas Lüftinger, et al.
Antibiotics (Basel, Switzerland)|April 23, 2022
Population Pharmacokinetic Model of Piperacillin in Critically Ill Patients and Describing Interethnic Variation Using External ValidationCristina Sanches, Geisa C S Alves, Andras Farkas, et al.
Antibiotics (Basel, Switzerland)|January 21, 2022
Effect of Different Piperacillin-Tazobactam Dosage Regimens on Synergy of the Combination with Tobramycin against <i>Pseudomonas aeruginosa</i> for the Pharmacokinetics of Critically Ill Patients in a Dynamic Infection ModelJessica R Tait, Hajira Bilal, Kate E Rogers, et al.
Intensive Care Medicine|April 15, 2017
The role of infection models and PK/PD modelling for optimising care of critically ill patients with severe infectionsT Tängdén, V Ramos Martín, T W Felton, et al.
The Journal of Antimicrobial Chemotherapy|June 19, 2026
A multicentre evaluation of pharmacokinetic/pharmacodynamic target attainment of piperacillin and tazobactam and the association with clinical outcomes in critically ill patients with sepsis and septic shockHelmi Sulaiman, Saskia A Wölky, Muhammad Azrai Rozali, et al.
Intensive Care Medicine|September 1, 2025
Antibiotic therapy for severe bacterial infectionsJean-François Timsit, Lowell Ling, Etienne de Montmollin, et al.
Pageof 61

Showing results (541-550 of 609) with videos related to

Sort By:
Pageof 61
Intensive Care Medicine|November 30, 2019
Antimicrobial de-escalation in critically ill patients: a position statement from a task force of the European Society of Intensive Care Medicine (ESICM) and European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Critically Ill Patients Study Group (ESGCIP)Alexis Tabah, Matteo Bassetti, Marin H Kollef, et al.
Trials|January 28, 2015
Meropenem versus piperacillin-tazobactam for definitive treatment of bloodstream infections due to ceftriaxone non-susceptible Escherichia coli and Klebsiella spp (the MERINO trial): study protocol for a randomised controlled trialPatrick N A Harris, Anton Y Peleg, Jon Iredell, et al.
Anesthesiology|March 2, 2017
Nebulization of Antiinfective Agents in Invasively Mechanically Ventilated Adults: A Systematic Review and Meta-analysisCandela Solé-Lleonart, Jean-Jacques Rouby, Stijn Blot, et al.
Clinical Pharmacokinetics|February 1, 2015
Reporting Guidelines for Clinical Pharmacokinetic Studies: The ClinPK StatementSalmaan Kanji, Meghan Hayes, Adam Ling, et al.
Microbiology Spectrum|January 9, 2024
Rapid nanopore sequencing and predictive susceptibility testing of positive blood cultures from intensive care patients with sepsisPatrick N A Harris, Michelle J Bauer, Lukas Lüftinger, et al.
Antibiotics (Basel, Switzerland)|April 23, 2022
Population Pharmacokinetic Model of Piperacillin in Critically Ill Patients and Describing Interethnic Variation Using External ValidationCristina Sanches, Geisa C S Alves, Andras Farkas, et al.
Antibiotics (Basel, Switzerland)|January 21, 2022
Effect of Different Piperacillin-Tazobactam Dosage Regimens on Synergy of the Combination with Tobramycin against <i>Pseudomonas aeruginosa</i> for the Pharmacokinetics of Critically Ill Patients in a Dynamic Infection ModelJessica R Tait, Hajira Bilal, Kate E Rogers, et al.
Intensive Care Medicine|April 15, 2017
The role of infection models and PK/PD modelling for optimising care of critically ill patients with severe infectionsT Tängdén, V Ramos Martín, T W Felton, et al.
The Journal of Antimicrobial Chemotherapy|June 19, 2026
A multicentre evaluation of pharmacokinetic/pharmacodynamic target attainment of piperacillin and tazobactam and the association with clinical outcomes in critically ill patients with sepsis and septic shockHelmi Sulaiman, Saskia A Wölky, Muhammad Azrai Rozali, et al.
Intensive Care Medicine|September 1, 2025
Antibiotic therapy for severe bacterial infectionsJean-François Timsit, Lowell Ling, Etienne de Montmollin, et al.
Pageof 61